Bristol Myers Squibb Drug Shows Positive Phase 3 Results for Idiopathic Pulmonary Fibrosis

Bristol Myers Squibb announced its investigational drug, admilparant, met its primary endpoint in the Phase 3 ALOFT-IPF trial for idiopathic pulmonary fibrosis (IPF). The oral LPA1 antagonist significantly improved forced vital capacity (FVC) at Week 52 compared to placebo, with a favorable safety profile. This positive outcome moves the drug closer to potential regulatory submission for a debilitating lung disease.